Piper says ImmunoGen's 'modest' timeline slip makes cash runway 'more tenuous' After ImmunoGen reported Q1 results and said that timelines around mirvetuximab's pivotal and confirmatory studies in platinum-resistant ovarian cancer have been pushed slightly out due to a COVID-related enrollment slowdown, Piper Sandler analyst Joseph Catanzaro said the "modest slip" in timelines makes the company's current cash runway "perhaps a bit more tenuous." While he said he continues to "take a glass half full" view, Catanzaro keeps a Neutral rating and $6.50 price target on ImmunoGen shares.
Leerink Partners analyst Jonathan Chang maintained a Hold rating on Immunogen on Monday, setting a price target of $6
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Immunogen on Tuesday, setting a price target of $12
Canaccord Genuity maintained a Buy rating on ImmunoGen, with a price target of $12.00